Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for FLUOROESTRADIOL F-18
- Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
- FES BPET-DBT in Newly Diagnosed Breast Cancer
- Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer
- 4FMFES-PET Imaging of Endometrial and Ovarian Cancers
- [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
- Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
- Evaluation of Endometriosis With 18F-fluoroestradiol PET / MRI
- [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
- FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
- Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer
- Phase 1 / 2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
- Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET
- [18F]FES PET/CT in PAH
- [18F]FES PET/CT in Endocrine Refractory Breast Cancer
- FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
- 18F-FES PET/CT in Imaging Patients With Desmoid Tumors
- F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
- Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer
- Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status
- Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
- FES-PET for Patients Treated on NCI Protocol 8762
- Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer
- Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
Clinical trials list
click for details